294 related articles for article (PubMed ID: 29079713)
1. A common mechanism for CFTR potentiators.
Yeh HI; Sohma Y; Conrath K; Hwang TC
J Gen Physiol; 2017 Dec; 149(12):1105-1118. PubMed ID: 29079713
[TBL] [Abstract][Full Text] [Related]
2. On the mechanism of gating defects caused by the R117H mutation in cystic fibrosis transmembrane conductance regulator.
Yu YC; Sohma Y; Hwang TC
J Physiol; 2016 Jun; 594(12):3227-44. PubMed ID: 26846474
[TBL] [Abstract][Full Text] [Related]
3. Physiological and pharmacological characterization of the N1303K mutant CFTR.
DeStefano S; Gees M; Hwang TC
J Cyst Fibros; 2018 Sep; 17(5):573-581. PubMed ID: 29887518
[TBL] [Abstract][Full Text] [Related]
4. Identifying the molecular target sites for CFTR potentiators GLPG1837 and VX-770.
Yeh HI; Qiu L; Sohma Y; Conrath K; Zou X; Hwang TC
J Gen Physiol; 2019 Jul; 151(7):912-928. PubMed ID: 31164398
[TBL] [Abstract][Full Text] [Related]
5. Synergistic Potentiation of Cystic Fibrosis Transmembrane Conductance Regulator Gating by Two Chemically Distinct Potentiators, Ivacaftor (VX-770) and 5-Nitro-2-(3-Phenylpropylamino) Benzoate.
Lin WY; Sohma Y; Hwang TC
Mol Pharmacol; 2016 Sep; 90(3):275-85. PubMed ID: 27413118
[TBL] [Abstract][Full Text] [Related]
6. Modulation of CFTR gating by permeant ions.
Yeh HI; Yeh JT; Hwang TC
J Gen Physiol; 2015 Jan; 145(1):47-60. PubMed ID: 25512598
[TBL] [Abstract][Full Text] [Related]
7. Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle.
Jih KY; Hwang TC
Proc Natl Acad Sci U S A; 2013 Mar; 110(11):4404-9. PubMed ID: 23440202
[TBL] [Abstract][Full Text] [Related]
8. Structural mechanisms for defective CFTR gating caused by the Q1412X mutation, a severe Class VI pathogenic mutation in cystic fibrosis.
Yeh JT; Yu YC; Hwang TC
J Physiol; 2019 Jan; 597(2):543-560. PubMed ID: 30408177
[TBL] [Abstract][Full Text] [Related]
9. Discovery of N-(3-Carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-lH-pyrazole-5-carboxamide (GLPG1837), a Novel Potentiator Which Can Open Class III Mutant Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Channels to a High Extent.
Van der Plas SE; Kelgtermans H; De Munck T; Martina SLX; Dropsit S; Quinton E; De Blieck A; Joannesse C; Tomaskovic L; Jans M; Christophe T; van der Aar E; Borgonovi M; Nelles L; Gees M; Stouten P; Van Der Schueren J; Mammoliti O; Conrath K; Andrews M
J Med Chem; 2018 Feb; 61(4):1425-1435. PubMed ID: 29148763
[TBL] [Abstract][Full Text] [Related]
10. The two ATP binding sites of cystic fibrosis transmembrane conductance regulator (CFTR) play distinct roles in gating kinetics and energetics.
Zhou Z; Wang X; Liu HY; Zou X; Li M; Hwang TC
J Gen Physiol; 2006 Oct; 128(4):413-22. PubMed ID: 16966475
[TBL] [Abstract][Full Text] [Related]
11. Differential thermostability and response to cystic fibrosis transmembrane conductance regulator potentiators of human and mouse F508del-CFTR.
Bose SJ; Bijvelds MJC; Wang Y; Liu J; Cai Z; Bot AGM; de Jonge HR; Sheppard DN
Am J Physiol Lung Cell Mol Physiol; 2019 Jul; 317(1):L71-L86. PubMed ID: 30969810
[TBL] [Abstract][Full Text] [Related]
12. Potentiation of the cystic fibrosis transmembrane conductance regulator by VX-770 involves stabilization of the pre-hydrolytic, O
Langron E; Prins S; Vergani P
Br J Pharmacol; 2018 Oct; 175(20):3990-4002. PubMed ID: 30107029
[TBL] [Abstract][Full Text] [Related]
13. G551D and G1349D, two CF-associated mutations in the signature sequences of CFTR, exhibit distinct gating defects.
Bompadre SG; Sohma Y; Li M; Hwang TC
J Gen Physiol; 2007 Apr; 129(4):285-98. PubMed ID: 17353351
[TBL] [Abstract][Full Text] [Related]
14. Mutation-specific dual potentiators maximize rescue of CFTR gating mutants.
Veit G; Da Fonte DF; Avramescu RG; Premchandar A; Bagdany M; Xu H; Bensinger D; Stubba D; Schmidt B; Matouk E; Lukacs GL
J Cyst Fibros; 2020 Mar; 19(2):236-244. PubMed ID: 31678009
[TBL] [Abstract][Full Text] [Related]
15. GLPG1837, a CFTR potentiator, in p.Gly551Asp (G551D)-CF patients: An open-label, single-arm, phase 2a study (SAPHIRA1).
Davies JC; Van de Steen O; van Koningsbruggen-Rietschel S; Drevinek P; Derichs N; McKone EF; Kanters D; Allamassey L; Namour F; de Kock H; Conrath K
J Cyst Fibros; 2019 Sep; 18(5):693-699. PubMed ID: 31147302
[TBL] [Abstract][Full Text] [Related]
16. CFTR potentiators: from bench to bedside.
Jih KY; Lin WY; Sohma Y; Hwang TC
Curr Opin Pharmacol; 2017 Jun; 34():98-104. PubMed ID: 29073476
[TBL] [Abstract][Full Text] [Related]
17. Potentiation of the cystic fibrosis transmembrane conductance regulator Cl
Wang Y; Cai Z; Gosling M; Sheppard DN
Am J Physiol Lung Cell Mol Physiol; 2018 Nov; 315(5):L846-L857. PubMed ID: 30136610
[TBL] [Abstract][Full Text] [Related]
18. Two rare variants that affect the same amino acid in CFTR have distinct responses to ivacaftor.
Li H; Rodrat M; Al-Salmani MK; Veselu DF; Han ST; Raraigh KS; Cutting GR; Sheppard DN
J Physiol; 2024 Jan; 602(2):333-354. PubMed ID: 38186087
[TBL] [Abstract][Full Text] [Related]
19. Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner.
Eckford PD; Li C; Ramjeesingh M; Bear CE
J Biol Chem; 2012 Oct; 287(44):36639-49. PubMed ID: 22942289
[TBL] [Abstract][Full Text] [Related]
20. Potentiator synergy in rectal organoids carrying S1251N, G551D, or F508del CFTR mutations.
Dekkers JF; Van Mourik P; Vonk AM; Kruisselbrink E; Berkers G; de Winter-de Groot KM; Janssens HM; Bronsveld I; van der Ent CK; de Jonge HR; Beekman JM
J Cyst Fibros; 2016 Sep; 15(5):568-78. PubMed ID: 27160424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
